Aprea Therapeutics Inc., of Boston, said it priced its IPO of approximately 5.7 common shares at $15 apiece, the midpoint of its proposed range, for expected gross proceeds of approximately $85 million. The company granted underwriters a 30-day option to purchase up to 850,000 additional shares, potentially adding about $12.8 million to the raise.